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Abstract
Rare sequence variants in the non-coding part of the BRCA genes are often reported as variants of uncertain significance
(VUS), which leave patients and doctors in a challenging position. The aim of this study was to determine the pathogenicity
of the BRCA1 c.5407-25T>A variant found in 20 families from Norway, France and United States with suspected hereditary
breast and ovarian cancer. This was done by combining clinical and family information with allele frequency data, and
assessment of the variant’s effect on mRNA splicing. Mean age at breast (n= 12) and ovarian (n= 11) cancer diagnosis in
female carriers was 49.9 and 60.4 years, respectively. The mean Manchester score in the 20 families was 16.4. The allele
frequency of BRCA1 c.5407-25T>A was 1/64,566 in non-Finnish Europeans (gnomAD database v2.1.1). We found the
variant in 1/400 anonymous Norwegian blood donors and 0/784 in-house exomes. Sequencing of patient-derived cDNA
from blood, normal breast and ovarian tissue showed that BRCA1 c.5407-25T>A leads to skipping of exon 23, resulting in
frameshift and protein truncation: p.(Gly1803GlnfsTer11). Western blot analysis of transiently expressed BRCA1 proteins in
HeLa cells showed a reduced amount of the truncated protein compared with wild type. Noteworthily, we found that a small
amount of full-length transcript was also generated from the c.5407-25T>A allele, potentially explaining the intermediate
cancer burden in families carrying this variant. In summary, our results show that BRCA1 c.5407-25T>A leads to partial
skipping of exon 23, and could represent a likely pathogenic variant with reduced penetrance.
Introduction
Since the identification of the BRCA1 gene in 1994 [1] and
the BRCA2 gene in 1995 [2], clinical testing of these genes
has been performed to identify people with high hereditary
risk of breast and ovarian cancer [3]. Cancer patients with a
pathogenic BRCA variant may benefit from targeted
therapy with polyadenosine-diphosphate ribose polymerase
(PARP) inhibitors, and non-affected carriers may be offered
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risk-reducing surgery [4, 5]. However, this is not the case if
the genetic test reveals a BRCA variant of uncertain clinical
significance (VUS), which is clinically not actionable
according to current guidelines [6]. With increasing use of
genetic testing, an increasing number of rare sequence var-
iants are detected. Because of the major clinical impact of
distinguishing between a BRCA (likely) pathogenic variant
and a VUS [6], substantial effort is put into the interpretation
of rare variants in diagnostic genetic laboratories every day.
Rare variants in non-coding parts of the genes are especially
difficult to interpret, and often have limited functional
information resulting in a classification of VUS [7].
The BRCA1 NG_005905.2 (NM_007294.3) c.5407-
25T>A variant is located in intron 22 (using traditional
numbering 1,2,3,5–24 of the exons). In ClinVar, the variant
is registered as VUS by three submitters (https://www.ncbi.
nlm.nih.gov/clinvar/variation/371817/). Previously, BRCA1
c.5407-25T>A has been classified as a VUS in two scien-
tific publications [8, 9], and as likely pathogenic in two
other papers, including our recent work on genetic testing
results from the DNA-BONus study [10, 11]. Our classifi-
cation was based on clinical data and cDNA analysis per-
formed in 2006 of the first patient identified with this
variant in our diagnostic laboratory. This analysis indicated
that BRCA1 c.5407-25T>A leads to skipping of exon 23
and a subsequently premature stop in exon 24, predicting a
non-functional BRCA1 protein (not published).
However, the interpretation of variants that impact spli-
cing is not straightforward. Over the years, there have been
several reports of variation in splicing of BRCA1 [12–15],
and the natural occurrence of alternative transcripts needs to
be taken into consideration when interpreting variants for
their spliceogenic potential [16]. Furthermore, many of
these variants may also produce variable amounts of normal
transcript in addition to an aberrant transcript, potentially
retaining some tumour-suppressor effect [17, 18]. Accord-
ing to suggested guidelines, such variants should be clas-
sified as VUS in the absence of clinical evidence of
pathogenicity [16, 18, 19].
The aim of this study was to determine the pathogenicity
of the BRCA1 c.5407-25T>A variant by assessing its effect
on mRNA splicing combined with allele frequency data and
clinical information from families with this variant.
Materials and methods
Patient materials and clinical assessment
Families counselled for hereditary breast and ovarian cancer
were recruited from Haukeland University Hospital and
Oslo University Hospital in Norway, Hospices Civils de
Lyon in France and Allegheny Health Network, Pittsburgh,
PA in the United States. They were included in the study if
the intronic BRCA1 c.5407-25T>A variant was identified in
at least one of the family members before June 1st 2019. All
patients signed written informed consent for genetic testing
and received genetic counselling. We collected clinical
information and family history from the patients’ medical
files. To evaluate if the cancer burden was consistent with a
potential pathogenic BRCA variant running in the family, all
families were rated by the Manchester Scoring System [20].
Control materials
Anonymous blood donors from Haukeland University
Hospital were used as controls for DNA and RNA analyses.
Variant allele frequency in population databases
The variant allele frequencies were retrieved from the
gnomAD database (http://gnomad.broadinstitute.org/) as
well as from an in-house database containing 784 exome
analyses from patients referred to diagnostic testing for
different non-cancer disorders. The patients in the in-house
database were predominantly Norwegian, and the region of
interest had a sequence coverage >20×.
DNA and RNA analyses
Genomic DNA was extracted from blood using Qia-
Symphony (Qiagen, Hilden, Germany). RNA was extracted
from blood using the PAX-gene kit (Qiagen) and from
normal breast and ovary tissues as well as cultured cells
using the RNeasy kit (Qiagen). cDNA synthesis was per-
formed using SuperScript (Thermo Fisher Scientific, Wal-
tham, MA, USA) as described by the manufacturer. For
RNA splicing analysis, cDNA was PCR-amplified by pri-
mers located in exon 17/18 and in the 3′UTR region
(BRCA1c5069rnaF2 and BRCA1c5592*158rnaR2, see
Supplementary Table S1). The PCR products were analysed
by agarose gel electrophoresis and Sanger sequencing. The
reference sequence NG_005905.2 (NM_007294.3) and
traditional numbering of exons [1–3, 5–24] was used.
The specific expression of BRCA1 full-length transcript
generated from the c.5407-25T>A allele was analysed by
assessing the presence of a SNP (c.4837A>G) in BRCA1
exon 16. For this purpose, the BRCA1c4753F primer loca-
ted upstream of c.4837A>G and the BRCA1c5441R primer
located in exon 23 (Supplementary Table S1) were used for
PCR amplification. The resulting PCR products were ana-
lysed by Sanger sequencing and NGS. PCR products pro-
duced at different numbers of PCR cycles (30 and 35) were
used as template for the Sanger sequencing, and the
sequences were analysed using the SeqPilot Software (JSI
medical systems, Ettenheim, Germany).
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For the NGS analysis, the PCR products generated after
30 cycles of amplification were sequenced using the Illu-
mina Flex library kit and the NextSeq500 sequencer (Illu-
mina, San Diego, CA, USA).
Sequences mapping to the BRCA1 region were also
extracted from data collected after full transcription
sequencing of total RNA purified from blood [21], using
Illumina TruSeq Stranded Total RNA with Ribo-Zero
Globin for library preparation, and sequenced on the
HiSeq 4000 Sequencing System (Illumina).
The data described in this study have been submitted to




Long-range PCR was performed by Expand™ Long Tem-
plate PCR System (Roche, Mannheim, Germany) using
patient-based TA clones containing cDNA corresponding to
BRCA1 wild type and p.Gly1803GlnfsTer11 as template,
and the primers BRCA1kozakwtc1F, BRCA1wtc5589* and
BRCA1c5407-25, as listed in Supplementary Table 1. The
final PCR products were TA-cloned into the eukaryotic
expression vector pcDNA3.1/V5-His TOPO (Thermo
Fisher Scientific), according to the manufacturer’s instruc-
tions. The empty vector pcDNA3.1 V5 was used as a
negative control. The expected molecular weight including
the V5 tag is ~230 kDa for the BRCA1 wild-type protein,
and 223 kDa for the predicted truncated protein p.
Gly1803GlnfsTer11.
Expression of BRCA1 in HeLa cells
HeLa cells (ATCC, Manassas, VA, USA) were cultured in
DMEM supplemented with 10% FBS. Transfection was
performed using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s instructions. Cells were harvested
and lysed in RIPA buffer (for western blot analysis) after
48 h. RNA expression of BRCA1 (assay ID Hs01556185,
Thermo Fisher Scientific) and the two housekeeping genes
GAPDH (Hs02786624_g1) and B2M (Hs00187842_m1)
was quantified using TaqMan technology and ABI Prism
7900 HT Fast Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA), according to the manu-
facturer’s protocol.
Controls without template cDNA were included in each
assay. Protein samples were separated on NuPAGE 3–8%
Tris-acetate protein gels (Thermo Fisher Scientific) and
blotted onto nitrocellulose membranes (Thermo Fisher
Scientific). The membranes were probed with anti-V5
(Thermo Fisher Scientific) or anti-β-actin (sc-47778, Santa
Cruz Biotechnology, Dallas, TX, USA) as loading control
in combination with HRP-conjugated second antibody goat
anti-mouse (SC 516102, Santa Cruz Biotechnology). Sig-
nals were detected using SuperSignal West Pico PLUS
Chemiluminescent Substrate (Thermo Fisher Scientific).
Results
Patients and clinical assessment
In this study we included 20 apparently unrelated families
carrying the BRCA1 c.5407-25T>A variant, 16 from Nor-
way, three from France and one from USA. In total 66
individuals were proven or obligate carriers of the variant.
Among the 49 female carriers, 23 (46.9%) were affected by
breast (n= 12) or ovarian (n= 11) cancer, with mean age of
49.9 years (standard deviation (SD): 9.9, 95% confidence
interval (CI): (43.6, 56.2)) at breast cancer diagnosis and
60.4 years (SD 11.3, 95% CI: (52.8, 67.9)) at ovarian cancer
diagnosis. Among the 26 unaffected female carriers, seven
were 50 years or older without having undergone prophy-
lactic surgery. Key clinical information for the 20 families is
summarised in Table 1. The family histories resulted in a
mean Manchester score of 16.4 (SD 9.2).
Variant allele frequency
The BRCA1 c.5407-25T>A variant was identified in 1 out
of 400 anonymous blood donors, but was not detected in
any of the 784 (non-cancer) patients included in an in-house
diagnostic exome database. In the gnomAD database
(v2.1.1), the allele frequency of this variant is reported to be
1/141,398 in total and 1/64,566 in the non-Finnish Eur-
opean population (http://gnomad.broadinstitute.org).
RNA analyses
cDNA synthesis from blood-derived RNA followed by PCR
amplification (of BRCA1) and agarose gel electrophoresis
showed a single band with the expected wild-type mole-
cular weight in 30 anonymous controls (Fig. 1a). In con-
trast, two bands were detected in patients heterozygous for
the c.5407-25T>A variant (Fig. 1a). DNA sequencing of the
PCR product from controls confirmed the presence of a
wild-type spliced BRCA1 sequence containing exon 23.
Sequencing of the two products from carriers of the BRCA1
c.5407-25T>A variant showed both a normal transcript and
a transcript lacking exon 23 (r.5407_5467del) (Fig. 1b).
This exon skipping (loss of 61 bp) results in a shift in the
reading frame and predicts a truncated BRCA1 protein p.
(Gly1803GlnfsTer11). In addition, RNA was extracted from
normal breast and ovarian tissue from two carriers of the
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BRCA1 c.5407-25T>A variant who had undergone risk-
reducing surgery. Agarose gel electrophoresis and sequen-
cing of the cDNA- based PCR products showed the pre-
sence of both a transcript containing exon 23 and a
transcript lacking exon 23, as seen in blood.
Blood-derived RNA from one of the c.5407-25T>A
carriers and three normal controls was analysed by full-
transcriptome sequencing. Out of ~200 million reads totally
in the sample, only a limited number of reads mapped to the
BRCA1 sequence. In the carrier, 4 reads showed a transcript
lacking exon 23, and 5 reads showed a transcript containing
exon 23. Among the normal controls, there were no tran-
scripts lacking exon 23.
Gel electrophoresis of the PCR products indicated that
there was some difference in the amount of transcript con-
taining exon 23 and transcript lacking exon 23 (Fig. 1a). To
investigate if this could be the result of reduced stability of
the transcript lacking exon 23, or caused by only partial
mis-splicing of the mRNA transcribed from the variant
allele, we studied three individuals heterozygous for a SNP
(c.4837A>G) in the transcribed sequence located close to
exon 23 in BRCA1 (Fig. 2). Selective PCR amplification
using a reverse primer located within exon 23 followed by
Sanger sequencing of only the transcript containing exon
23, showed a small additional peak in the SNP position,
demonstrating that a small amount of correctly spliced
transcript including exon 23 was generated from the c.5407-
25T>A allele. To quantitate the amount of full-length
BRCA1 transcript including exon 23 expressed from the
variant allele, the PCR products amplified from RNA
(cDNA) were sequenced both by Sanger and NGS tech-
nology. NGS-based sequencing of blood-derived RNA
from three different carriers showed that the full-length
transcript from the variant allele represented 10–13% of the
total full-length transcript. Sequencing of RNA isolated
from normal breast tissue from one of the carriers showed
that full-length transcript from the variant allele represented
20% of the total full-length transcript. Sequencing of blood-
derived RNA from a normal control showed that the two
alleles were expressed at approximately the same levels
(Supplementary Table S2). Comparable results were
obtained from Sanger sequencing of PCR products gener-
ated after 30 and 35 cycles of amplification (results not
shown).
Protein analysis
Western blot analysis after transient expression in HeLa
cells with plasmid encoding wild-type BRCA1 and the
truncated protein p.Gly1803GlnfsTer11 is shown in Sup-
plementary Fig. S1. Both proteins revealed bands at
expected positions according to molecular weight. After
Table 1 Characteristics of 20 families from Norway, France and the United States with the BRCA1 c.5407-25T>A variant.
Family Index cancer
diagnosis
Cancer diagnosis in first-degree
relative, if index unaffected
Age at cancer diagnosis
of index casea
Pathology of index cancera Manchester
scoreb
1 Female breastc 45–50 Ductal carcinoma, Er+/Pr+/Her2–, grade 1 4
2 Ovarian 35–40 Not available 14
3 Carcinomatosis, suspected
ovarian cancer
55–60 Not available 21
4 Ovarian 45–50 Serous papillary cystadenocarcinoma 30
5 Ovarian 60–65 Serous papillary carcinoma, grade 3 12
6 Breast 30–35 Not available 18
7 Female breastc 60–65 Infiltrating ductal carcinoma, Er+/Pr+/Her2–, grade 1 19
8 Breast 65–70 Adenocarcinoma 8
9 Female breast 45–50 Infiltrating ductal carcinoma, triple negative 10
10 Ovarian 60–65 Serous papillary carcinoma, grade 3 12
11 Ovarian 65–70 High-grade serous 15
12 Ovarian 55–60 Granulosa cell tumour 26
13 Female breast 55–60 DCIS, grade 3 12
14 Female breast 50–55 Infiltrating ductal and DCIS, Er+/Pr+/ Her2– 31
15 Ovarian 60–65 High-grade serous 12
16 Male breast 45–50 Invasive ductal adenocarcinoma, grade 2 HR+/Her2– 20
17 Female breast 35–40 Ductal carcinoma, Er+/Pr+/Her2–, grade 3 17
18 Female breast 55–60 Lobular carcinoma, Er+/Pr+/Her2–, grade 2 3
19 Female breast 60–65 Infiltrating carcinoma, triple negative 6
20 Female breast 45–50 Multifocal lobular carcinoma and Er+/Pr+/Her2–,
grade 2
37
aDiagnosis in first-degree relative, if the index was unaffected.
bCombined Manchester score calculated as described in Evans et al. (MSS3) [20].
cPreviously reported in Høberg-Vetti et al. [10].
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correction for mRNA expression levels, the truncated pro-
tein p.Gly1803GlnfsTer11 was less abundant than the wild
type. This indicates reduced protein stability for the
p.Gly1803GlnfsTer11, as expected for truncated variants.
Discussion
We have identified the intronic BRCA1 variant c.5407-25T>A
in 20 families recruited from cancer genetics clinics. Based on
the results of the current study, we believe this variant is likely
pathogenic with possibly reduced penetrance.
Families with BRCA1 c.5407-25T>A had clinical char-
acteristics resembling other BRCA-positive families. The
mean age (95% CI) of the onset of breast and ovarian cancer
was 49.9 (43.6, 56.2) and 60.4 (52.8, 67.9) years, respec-
tively. This is lower than the corresponding mean age of
diagnosis in the general population, which in Norway was
62.1 years for breast cancer and 64.9 years for ovarian
cancer in the years 2013–2017, according to the Norwegian
Cancer Registry [22]. However, it is higher than reported in
a large international prospective study of clinically ascer-
tained carriers of a BRCA1 pathogenic variant, with median
age at diagnosis of breast and ovarian cancer of 44 and 54
years, respectively [23]. On the other hand, a recent large
study on unselected women with breast cancer in Sweden
found a mean age at diagnosis of 50.3 years in women with
a pathogenic BRCA1 variant [24]. This illustrates that the
penetrance of BRCA1 pathogenic variants may differ,
depending on the mode of ascertainment. The carriers of
BRCA1 c.5407-25T>A in our study were ascertained from
families undergoing genetic testing and counselling for
hereditary breast and ovarian cancer. Following the constant
development in genetics, the criteria for selecting patients
for BRCA genetic testing were more stringent when the first
patient with this variant was identified back in 2004, com-
pared with the clinical practice today [4, 5]. As an example,
while the Norwegian BRCA test criteria in 2004 corre-
sponded to a Manchester score of 16, the 2019 criteria
correspond to a Manchester score of 4 [4]. The Manchester
scoring system takes into account age-dependent occurrence
of cancer in the breasts, ovaries, pancreas and prostate in all
family members under the condition of an autosomal-
dominant inheritance pattern. In general, a higher Man-
chester score indicates higher probability of a pathogenic
BRCA variant being present, e.g. a score above 15
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Fig. 1 Detection of BRCA1 transcript lacking exon 23 in BRCA1
c.5407-25T>A carrier. a Agarose gel electrophoresis of PCR pro-
ducts amplified from cDNA using primers located in exon 17/18 and
in the 3′UTR showed a single band with the expected length (708 bp)
for the control. In the heterozygous carrier of the c.5407-25T>A
variant, one additional shorter band of 648 bp was detected. b Sanger
sequencing of the product from the control confirmed the presence of a
wild-type spliced BRCA1 sequence including exon 23. Sequencing of
the two products from the c.5407-25T>A carrier showed both a normal
transcript and a transcript lacking exon 23.
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corresponds to 10% probability [20]. We found a mean
Manchester score of 16.4 in the 20 families with BRCA1
c.5407-25T>A. This is noteworthily higher than the mean
score of 8.3 in unselected patients with sporadic breast or
ovarian cancer and a negative BRCA genetic test result (n=
462) in our previous DNA-BONus study [10], although the
two groups are not directly comparable, given the calcula-
tions in the latter group were based on a more limited family
history and did not adjust for pathology information. In the
same DNA-BONus study, the mean Manchester score was
23.3 in patients where a truncating pathogenic BRCA var-
iant was found in previously unrecognised BRCA families
(n= 19). Altogether, these Manchester scores could indi-
cate an intermediate cancer burden in families with BRCA1
c.5407-25T>A, higher than for average patients with breast
and ovarian cancer, but lower than for families with trun-
cating BRCA variants.
Despite our finding of the variant in 1 out of 400
anonymous blood donors, the low frequency of 1/64,566 in
the normal non-Finnish European population (http://gnoma
d.broadinstitute.org) indicates that BRCA1 c.5407-25T>A
should not be considered a benign common variant.
In contrast to computer tools that did not predict any
effect of this variant on RNA splicing, our results based on
RNA extracted from blood, breast and ovarian tissue clearly
show that BRCA1 c.5407-25T>A causes skipping of exon
23. The molecular mechanism for the observed exon
23 skipping is unclear, but the variant may cause a damage
to the branch site. However, computer predictions did not
show any strong evidence for this mechanism. The exon
skipping leads to frameshift and introduction of a premature
stop codon in exon 24. In the predicted truncated BRCA1
protein, p.Gly1803GlnfsTer11, the last 61 amino acids are
lost, including part of the BRCA1 carboxyl terminal
(BRCT) domain that is essential for the tumour-suppressor
function of BRCA1 [25]. This is in accordance with our
western blot analysis showing a slightly shorter band for the
p.Gly1803GlnfsTer11 protein as compared with wild-type
BRCA1 (Supplementary Fig. 1). After correction for RNA
levels, the p.Gly1803GlnfsTer11 showed lower protein
amounts as compared with wild-type protein, indicating
reduced protein stability.
Other variants that also lead to skipping of exon 23 have
been published as pathogenic, e.g. c.5407-2A>G [11, 26],
c.5407-10G>A [27], c.5467+1G>A [28] and c.5434C>G
(p.Pro1812Ala) [11, 29]. Although a wide range of alter-
native transcripts have been described for the BRCA1 locus
[12], there were no signs of aberrant splicing of exon 23
among the 30 normal controls in our study.
Noteworthily, the c.5407-25T>A allele generated a small
amount of correctly spliced transcript, including exon 23, in




Fig. 2 A small amount of
correctly spliced transcript
including exon 23 is generated
from the BRCA1 c.5407-
25T>A allele. a BRCA1 c.5407-
25T>A carrier shown to be
heterozygous for the SNP
rs1799966 (c.4837A>G) in exon
16 by PCR amplification and
sequencing of genomic DNA.
b A region including the SNP
rs1799966 was amplified by
selective PCR using a reverse
primer located within exon 23
and cDNA from the same
carrier. Sanger sequencing of
only the transcript containing
exon 23 showed a small
additional peak in the SNP
position, indicating that a
small amount of correctly
spliced transcript including
exon 23 is generated from the
c.5407-25T>A allele.
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breast tissue. According to the three-level classification of
splice variants introduced by Houdayer et al. [18], this
variant should be considered a class 2S variant (leaky splice
site mutation, partial effect). As suggested by Walker et al.
[19]. we performed a semi-quantitative calculation of the
variant allele contribution to full-length transcript—which
showed that 10–13% of the total full-length transcript in
blood (n= 3) and 20% in breast tissue (n= 1) was gener-
ated from the c.5407-25T>A allele.
According to previous studies, blood is a relevant source
of RNA for analyses of BRCA1 with respect to breast and
ovarian cancer [12, 14, 15]. This is supported by our finding
that BRCA1 c.5407-25T>A leads to skipping of exon 23,
both in breast and ovarian tissue, as well as in blood.
However, the semi-quantitative analysis indicated a slightly
higher proportion of full-length transcript generated from
the variant allele in breast tissue (20%) as compared with
blood (12%) from the same individual, but we do not know
if this represents a true expression difference.
The biological consequence of a small “leakage” of
normal transcript from a splice variant is not fully known,
but this could lead to synthesis of functional protein and
maintenance of some tumour-suppressor effect. Given this
background, class 2S splice variants are usually classified as
VUS [17–19]. On the other hand, it is reasonable to believe
that the decreased amount of normal transcript could lead to
a reduced, although not completely absent, tumour-
suppressor effect—of potential clinical significance. In
line with this, it is possible that the BRCA1 c.5407-25T>A
variant is associated with an increased risk of breast and
ovarian cancer, but the magnitude of risk may be lower than
for truncating pathogenic BRCA1 variants. Both the median
age at cancer diagnosis and the family histories in our
cohort are compatible with a reduced penetrance of BRCA1
c.5407-25T>A, although we were not able to calculate
precise penetrance estimates due to the small number of
patients. “Leaky” splice variants have been described to be
disease-causing with reduced penetrance for other genes
[30–32], and this could also be the case for BRCA1 and
BRCA2 [17]. However, to our knowledge, the correlation
between the ratio of abnormal/normal transcript generated
by a variant allele and the magnitude of cancer risk has so
far not been investigated systematically for BRCA splice
variants. The study of de la Hoya et al. indicated that a
BRCA1 allele producing up to 70–80% of transcript
encoding tumour-suppressor-deficient protein “may not
necessarily confer high-risk of developing cancer” [14]. The
classification of “leaky” splice variants is further compli-
cated by the discrepancy of results from different labora-
tories, most likely due to the use of different techniques and/
or experimental conditions. An illustrative example is the
BRCA1 c.5434C>G variant that has been reported to cause
complete skipping of exon 23 [18]. Another group showed
the same variant to cause partial skipping of exon 23 in
about 75% of transcripts [29].
Nevertheless, the BRCA1 variant c.5434C>G is con-
sidered a high-risk pathogenic/likely pathogenic variant by
several independent groups [11, 18, 29]. However, most
partial splice variants remain VUS [19], leaving patients
and doctors in a challenging position. While caution is
justified when considering prophylactic surgery in healthy
individuals carrying “leaky” BRCA splice variants, Gelli
et al. claim that such variants in patients with ovarian
cancer could serve as indication for treatment with PARP
inhibitors [17].
The existence of intermediate-penetrance variants in
high-risk genes has been described by the ENIGMA con-
sortium; the missense variant c.5096G>A (p.Arg1699Gln)
in BRCA1 has been demonstrated to be associated with a
lower risk of breast and ovarian cancer than truncating
variants [33]. Interestingly, we identified BRCA1
c.5096G>A in one woman with breast cancer and BRCA1
c.5407-25T>A in two women with breast cancer in our
previous DNA-BONus study, where all women with newly
diagnosed breast or ovarian cancer were offered BRCA
genetic testing, regardless of family history or age [10]. One
could speculate that a lower threshold for genetic testing
potentially could lead to identification of more variants
associated with moderate increased cancer risk, not only
pathogenic variants in moderate-risk genes, but also var-
iants with reduced penetrance in high-risk genes.
In summary, our results indicate that the intronic BRCA1
c.5407-25T>A variant causes partly skipping of exon 23,
and is a likely pathogenic variant with possible reduced
penetrance. Interpretation of splice variants is complex, but
should have high priority in diagnostic genetic laboratories.
Further studies on an extended number of families with
BRCA1 c.5407-25T>A are warranted to estimate the asso-
ciated cancer risk, which would be most helpful for the
clinical management of patients with this rare intronic
variant.
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